ArticleCancers2014
Recent advances in the molecular characterization of circulating tumor cells.
Article in Cancers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03979339 (Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers
Who cites it
30 citing papers in PubMed, 56 citations in OpenAlex.
- Circulating tumour cells and circulating tumour DNA in head and neck cancer: from molecular insights to clinical impact.Cancer metastasis reviews · 2025Review
- The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology.The journal of liquid biopsy · 2025Review
- Enhancing detection and monitoring of circulating tumor cells: Integrative approaches in liquid biopsy advances.The journal of liquid biopsy · 2025Review
- Advances in the role of circulating tumor cell heterogeneity in metastatic small cell lung cancer.Cancer innovation · 2024Review
- Article
- Article
- Liquid biopsy in pancreatic cancer: the beginning of a new era.Oncotarget · 2018Review
- Circulating Tumor Cell Analysis in Preclinical Mouse Models of Metastasis.Diagnostics (Basel, Switzerland) · 2018Review
- Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients.Cancer management and research · 2018Article
- Article
- Association of epithelial-to-mesenchymal transition circulating tumor cells in non-small cell lung cancer (NSCLC) molecular subgroups.Journal of thoracic disease · 2017Article
- Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer.Journal of thoracic disease · 2017Review
- Article
- Article
- Expression of SOCS1 and CXCL12 Proteins in Primary Breast Cancer Are Associated with Presence of Circulating Tumor Cells in Peripheral Blood.Translational oncology · 2016Article
- The potential for liquid biopsies in the precision medical treatment of breast cancer.Cancer biology & medicine · 2016Article
- Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors.Clinical & experimental metastasis · 2016Review
- Notes for developing a molecular test for the full characterization of circulating tumor cells.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2015Review
- A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.Journal of translational medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although circulating tumor cells (CTCs) were first observed over a century ago, lack of sensitive methodology precluded detailed study of these cells until recently. However, technological advances have now facilitated the identification, enumeration, and characterization of CTCs using a variety of methods. The majority of evidence supporting the use of CTCs in clinical decision-making has been related to enumeration using the CellSearch® system and correlation with prognosis. Growing evidence also suggests that CTC monitoring can provide an early indication of patient treatment response based on comparison of CTC levels before and after therapy. However, perhaps the greatest potential that CTCs hold for oncology lies at the level of molecular characterization. Clinical treatment decisions may be more effective if they are based on molecular characteristics of metastatic cells rather than on those of the primary tumor alone. Molecular characterization of CTCs (which can be repeatedly isolated in a minimally invasive fashion) provides the opportunity for a "real-time liquid biopsy" that allows assessment of genetic drift, investigation of molecular disease evolution, and identification of actionable genomic characteristics. This review focuses on recent advances in this area, including approaches involving immunophenotyping, fluorescence in situ hybridization (FISH), multiplex RT-PCR, microarray, and genomic sequencing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.